Says, Ashwani Singla, Founding Managing Partner, “In aftermath of the pandemic, health and wellness will see a major emphasis that will drive innovation across the entire healthcare continuum. Policy and Regulatory evolution will need to not only keep up but lead the way in achieving the nation’s agenda of universal health. As a PhD scholar pursuing public health and former Chairman of the National Pharma Pricing Authority(NPPA), Mr. Singh’s deep knowledge and expertise of the domain will be invaluable to our clients to achieve convergence of commercial and national interests.”
He adds, “Mr. Singh’s appointment is a feather in our cap as his illustrious career trajectory uniquely positions him to provide our clients guidance in the policy intersection between the State and the Central government.”


About Mr. Bhupendra Singh
Mr. Bhupendra Singh, has served the nation for over three decade in various capacities in the state of Uttar Pradesh, the Centre and prestigious international deputations. He brings extensive experience in the fields of industrial promotion, public enterprises, tourism, transport, agriculture, textiles, pharmaceuticals and public policy. He superannuated in December 2020 as Special Secretary and the Financial Advisor (Secretary Equivalent) to Ministry of Home Affairs, Personnel, PMO and NTRO.

In his illustrious career, he held several notable posts including that of the Chairman, National Pharmaceuticals Pricing Authority, (NPPA), Secretary General, International Jute Study Group (IJSG), Dhaka & Chairman, National Authority on Chemical Weapons Convention.

About Astrum’s Corporate Affairs Services: We support our clients in promoting legitimate business interests in a professional and ethical manner. Our Corporate Affairs Advisory team comprises of policy experts skilled and proficient to advise CXOs on the impact of political and policy developments and help shape the corporate affairs strategy in securing and promoting legitimate business interests ethically by engaging in a constructive and evidence-based dialogue with policy makers, regulators and influencers.